Format

Send to

Choose Destination
Vaccine. 2015 May 11;33(20):2354-9. doi: 10.1016/j.vaccine.2015.03.032. Epub 2015 Apr 1.

HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations.

Author information

1
CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France.
2
CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France; INSERM, Paris, France.
3
Bertin Pharma, Montigny-Le-Bretonneux, France.
4
Vaccine Research Institute (VRI), Créteil, France; INSERM, Paris, France; INSERM, Unite U955, Créteil F-94010, France; Université Paris-Est, Faculté de Médecine, Hôpital Albert-Chenevier, Créteil F-94010, France; Hôpital Henri-Mondor, Service d'Immunologie clinique, UMR-S 955, Créteil F-94010, France.
5
CEA, Division of Immuno-Virology, IDMIT Center, iMETI/DSV, Fontenay-aux-Roses, France; UMR-1184, Université Paris Sud 11, Orsay, France; Vaccine Research Institute (VRI), Créteil, France. Electronic address: roger.le-grand@cea.fr.

Abstract

We evaluated the immunogenicity of a prime/boost vaccine strategy combining 5 lipopeptides (HIV-Lipo-5) and a recombinant modified vaccinia virus Ankara (rMVA-HIV) in cynomolgus macaques. Both of these vaccine components deliver HIV LAI Gag, Pol, and Nef antigens. Systemic and local safety was excellent in all groups. Immunization with HIV-Lipo-5 alone induced significant serum anti-HIV antibody titers which were not modified by rMVA-HIV immunization. However, induction of T-cell responses, as measured by IFNγ and IL-2 producing cells upon short-term stimulation with HIV peptide pools, required combined immunization with rMVA-HIV. Responses were preferentially observed against Gag antigen. Interestingly, HIV-Lipo-5 efficiently primed HIV induced T-cell responses upon the injection of rMVA-HIV, which may help to reduce the required number of vector injections. Our results provide a rationale for the use of a strategy involving HIV-Lipo-5 priming followed by rMVA-HIV booster immunization as a prophylactic or therapeutic vaccine approach against HIV infection and AIDS.

KEYWORDS:

HIV; Lipopeptide; MVA; NHP

PMID:
25839103
DOI:
10.1016/j.vaccine.2015.03.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center